Tag: targeted therapy for metastatic NSCLC

Home / targeted therapy for metastatic NSCLC

Categories

Encorafenib with binimetinib is approved by the FDA for treatment of metastatic non-small cell lung cancer with a BRAF V600E mutation

The Food and Drug Administration (FDA) approved Encorafenib (Braftovi, Array BioPharma Inc., a wholly owned subsidiary of Pfizer) and binimetinib (Mektovi, Array BioPharma Inc.) in November 2023 as m...
targeted-therapy-for-metastatic-nsclc

Scan the code